InsiderTrades.com logo
Trading Experts Call It “The Perfect Tesla Trade”
From Wealthpress   |   Ad
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Click here for details,

ACRV Insider Trading

Insider Ownership Percentage: 7.30%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $35,718.97

Acrivon Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Acrivon Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Acrivon Therapeutics Share Price & Price History

Current Price: $5.03
Price Change: ▼ Price Decrease of -0.36 (-6.68%)
As of 12/8/2023 01:00 AM ET

This chart shows the closing price history over time for ACRV up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
All the trading advice you’ve ever received boils down to this
From DTI Trader   |   Ad
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Drop everything and learn about the Income Calendar now.

Acrivon Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/26/2023Ltd ChioneMajor ShareholderSell16$12.93$206.883,848,632View SEC Filing Icon  
6/14/2023Ltd ChioneMajor ShareholderSell893$12.13$10,832.093,850,704View SEC Filing Icon  
6/12/2023Ltd ChioneMajor ShareholderSell2,000$12.34$24,680.003,854,597View SEC Filing Icon  
11/17/2022Ltd ChioneMajor ShareholderBuy400,000$12.50$5,000,000.003,856,597View SEC Filing Icon  
11/17/2022Ra Capital Management, L.P.DirectorBuy3,389,500$12.50$42,368,750.004,384,206View SEC Filing Icon  
See Full Table
Trading Experts Call It “The Perfect Tesla Trade”
From Wealthpress   |   Ad
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Click here for details,

SEC Filings (Institutional Ownership Changes) for Acrivon Therapeutics (NASDAQ:ACRV)

68.54% of Acrivon Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ACRV by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Acrivon Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/13/2023Northern Trust Corp72,722$0.70M0.0%+5.9%0.328%Search for SEC Filing on Google Icon
11/13/2023Federated Hermes Inc.226,375$2.16M0.0%-25.6%1.020%Search for SEC Filing on Google Icon
11/8/2023Charles Schwab Investment Management Inc.67,661$0.65M0.0%+11.0%0.307%Search for SEC Filing on Google Icon
9/21/2023Barclays PLC14,263$0.18M0.0%-16.0%0.065%Search for SEC Filing on Google Icon
8/15/2023Wells Fargo & Company MN3,305$43K0.0%+108.1%0.015%Search for SEC Filing on Google Icon
8/15/2023Citadel Advisors LLC1,649,646$21.38M0.0%+0.5%7.522%Search for SEC Filing on Google Icon
8/14/2023State Street Corp125,976$1.63M0.0%+47.6%0.574%Search for SEC Filing on Google Icon
8/14/2023Nuveen Asset Management LLC11,821$0.15M0.0%N/A0.054%Search for SEC Filing on Google Icon
8/11/2023BlackRock Inc.533,355$6.91M0.0%+12.5%2.432%Search for SEC Filing on Google Icon
8/11/2023Geode Capital Management LLC178,453$2.31M0.0%+1.7%0.814%Search for SEC Filing on Google Icon
8/11/2023Northern Trust Corp68,678$0.89M0.0%-1.5%0.313%Search for SEC Filing on Google Icon
8/10/2023AAF Wealth Management LLC10,678$0.14M0.1%N/A0.049%Search for SEC Filing on Google Icon
8/10/2023Charles Schwab Investment Management Inc.60,958$0.79M0.0%+4.7%0.278%Search for SEC Filing on Google Icon
8/10/2023Citigroup Inc.2,790$36K0.0%+1,281.2%0.013%Search for SEC Filing on Google Icon
8/3/2023Barclays PLC14,263$0.18M0.0%-16.0%0.065%Search for SEC Filing on Google Icon
8/3/2023Bank of New York Mellon Corp24,795$0.32M0.0%+8.6%0.113%Search for SEC Filing on Google Icon
7/20/2023Exchange Traded Concepts LLC11,709$0.15M0.0%N/A0.053%Search for SEC Filing on Google Icon
5/18/2023JPMorgan Chase & Co.6,630$84K0.0%N/A0.030%Search for SEC Filing on Google Icon
5/18/2023New York State Common Retirement Fund2,206$28K0.0%N/A0.010%Search for SEC Filing on Google Icon
5/16/2023Susquehanna International Group LLP32,262$0.41M0.0%N/A0.147%Search for SEC Filing on Google Icon
5/16/2023State Street Corp85,339$1.08M0.0%N/A0.389%Search for SEC Filing on Google Icon
5/16/2023Geode Capital Management LLC175,404$2.23M0.0%N/A0.800%Search for SEC Filing on Google Icon
5/15/2023Deutsche Bank AG5,369$68K0.0%N/A0.024%Search for SEC Filing on Google Icon
5/12/2023BlackRock Inc.474,227$6.02M0.0%N/A2.162%Search for SEC Filing on Google Icon
5/12/2023Bank of America Corp DE5,856$74K0.0%N/A0.027%Search for SEC Filing on Google Icon
5/12/2023Wellington Management Group LLP888,130$11.14M0.0%-1.3%4.050%Search for SEC Filing on Google Icon
5/12/2023Charles Schwab Investment Management Inc.58,209$0.74M0.0%N/A0.265%Search for SEC Filing on Google Icon
5/9/2023Bank of New York Mellon Corp22,837$0.29M0.0%N/A0.104%Search for SEC Filing on Google Icon
5/9/2023California State Teachers Retirement System3,218$41K0.0%N/A0.015%Search for SEC Filing on Google Icon
5/8/2023Federated Hermes Inc.613,625$7.79M0.0%-25.5%2.798%Search for SEC Filing on Google Icon
5/4/2023Barclays PLC16,983$0.22M0.0%+310.0%0.077%Search for SEC Filing on Google Icon
2/16/2023HealthCor Management L.P.284,201$3.27M3.0%N/A1.360%Search for SEC Filing on Google Icon
2/15/2023Millennium Management LLC19,639$0.23M0.0%N/A0.094%Search for SEC Filing on Google Icon
2/14/2023RA Capital Management L.P.4,810,508$55.42M1.1%N/A23.028%Search for SEC Filing on Google Icon
2/14/2023Marshall Wace LLP1,223,252$14.09M0.0%N/A5.856%Search for SEC Filing on Google Icon
2/14/2023Two Sigma Investments LP21,534$0.25M0.0%N/A0.103%Search for SEC Filing on Google Icon
2/13/2023Barclays PLC4,142$47K0.0%N/A0.020%Search for SEC Filing on Google Icon
2/13/2023Sands Capital Ventures LLC1,652,605$19.04M5.2%N/A7.913%Search for SEC Filing on Google Icon
2/10/2023NEA Management Company LLC481,677$4.44M0.2%N/A2.306%Search for SEC Filing on Google Icon
2/8/2023UBS Group AG4,748$55K0.0%N/A0.023%Search for SEC Filing on Google Icon
2/1/2023Bank of Montreal Can42,444$0.55M0.0%N/A0.203%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Acrivon Therapeutics logo
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
Read More on Acrivon Therapeutics

Today's Range

Now: $5.03
Low: $4.82
High: $5.42

50 Day Range

MA: $5.36
Low: $3.63
High: $9.00

52 Week Range

Now: $5.03
Low: $3.41
High: $25.47

Volume

22,205 shs

Average Volume

32,324 shs

Market Capitalization

$111.62 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Acrivon Therapeutics?

Acrivon Therapeutics' top insider shareholders include:
  1. Ra Capital Management, LP (Director)
  2. Ltd Chione (Major Shareholder)
Learn More about top insider investors at Acrivon Therapeutics.

Who are the major institutional investors of Acrivon Therapeutics?

Acrivon Therapeutics' top institutional investors include:
  1. Federated Hermes Inc. — 1.02%
  2. Northern Trust Corp — 0.33%
  3. Charles Schwab Investment Management Inc. — 0.31%
Learn More about top institutional investors of Acrivon Therapeutics stock.

Which major investors are selling Acrivon Therapeutics stock?

In the previous quarter, ACRV stock was sold by these institutional investors:
  1. Federated Hermes Inc.

Which major investors are buying Acrivon Therapeutics stock?

In the previous quarter, ACRV stock was bought by institutional investors including:
  1. Charles Schwab Investment Management Inc.
  2. Northern Trust Corp
In the last year, these company insiders have bought Acrivon Therapeutics stock:
  1. Ra Capital Management, LP (Director)
  2. Ltd Chione (Major Shareholder)
Learn More investors buying Acrivon Therapeutics stock.
Trading Experts Call It “The Perfect Tesla Trade”
From Wealthpress   |   Ad
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Click here for details,